Addition of Standard Enzalutamide Medication Shows Synergistic Effects on Response to [
PSMA
enzalutamide
mCRPC
radioligand therapy
radiosensitizer
upregulation
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
29 May 2022
29 May 2022
Historique:
received:
12
04
2022
revised:
24
05
2022
accepted:
28
05
2022
entrez:
10
6
2022
pubmed:
11
6
2022
medline:
11
6
2022
Statut:
epublish
Résumé
Well-received strong efficacy of prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) does not prevent patients from either early or eventual disease progression under this treatment. In this study, we investigated co-medication with enzalutamide as a potential re-sensitizer for PSMA-RLT in patients with imminent treatment failure on standard
Identifiants
pubmed: 35681671
pii: cancers14112691
doi: 10.3390/cancers14112691
pmc: PMC9179420
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Nucl Med. 2019 Jul;60(7):950-954
pubmed: 30552200
Int J Clin Pract. 2011 Nov;65(11):1180-92
pubmed: 21995694
Target Oncol. 2021 May;16(3):369-380
pubmed: 33687624
J Nucl Med. 2016 Jul;57(7):1006-13
pubmed: 26795286
Cancers (Basel). 2022 Mar 26;14(7):
pubmed: 35406467
Eur J Nucl Med Mol Imaging. 2020 Mar;47(3):687-694
pubmed: 31901103
Prostate. 2015 Feb 15;75(3):242-54
pubmed: 25327687
Lancet. 2021 Feb 27;397(10276):797-804
pubmed: 33581798
Prostate. 2018 Jul;78(10):758-765
pubmed: 29633296
Int J Mol Sci. 2021 Jul 11;22(14):
pubmed: 34299051
J Nucl Med. 2017 Jan;58(1):85-90
pubmed: 27765862
J Nucl Med. 2017 Jan;58(1):81-84
pubmed: 27660139
EJNMMI Res. 2015 Dec;5(1):66
pubmed: 26576996
N Engl J Med. 2021 Sep 16;385(12):1091-1103
pubmed: 34161051
Nat Rev Cancer. 2015 Dec;15(12):701-11
pubmed: 26563462
EJNMMI Res. 2018 Oct 29;8(1):96
pubmed: 30374743
Eur Urol Oncol. 2018 May;1(1):78-82
pubmed: 31100231
Lancet Oncol. 2018 Jun;19(6):825-833
pubmed: 29752180
N Engl J Med. 2012 Sep 27;367(13):1187-97
pubmed: 22894553